Healthcare
Kestra Medical Technologies, Ltd.(KMTS)
Live Price
Offline$19.93
+4.45% today
Window Change
-2.49%
Window
May 29, 2026 → Jun 22, 2026
- Market Cap
- $1.27B
- Revenue Growth
- +115.1%
- EPS Growth
- -151.5%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars · May 29, 2026 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kestra Medical Technologies, Ltd. (KMTS) is a Healthcare stock with a market cap of $1.27B and listed on NASDAQ. The stock last traded around $19.93 and down 2.5% across the available one-year price window (May 29, 2026 → Jun 22, 2026). Baseline metrics include revenue growth of +115.1%, EPS growth of -151.5%, a dividend yield of 0.0%. What stands out right now is revenue +115.1%, EPS -151.5%, free cash flow -19.4% with operating margin -171.5% and ROIC -42.7%. Valuation already assumes a fairly strong business story at price/sales 15.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines KMTS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+115.1% vs +7.6% peer median
Operating Margin
Below sector median
-171.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +115.1% and EPS is at -151.5%, with operating margin around -171.5%.
Benchmark Edge
KMTS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KMTS
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KMTS Max Drawdown
-11.48%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KMTS and SPY.
Company Overview
Kestra Medical Technologies, Ltd.
NASDAQ Global Select
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
- Leadership
- Brian Webster
- IPO Date
- Mar 6, 2025
- Employees
- 300
- Street Address
- 3933 Lake Washington Blvd NE
- Mailing
- Kirkland, WA, 98033
- Region
- Kirkland, WA, US
- Reporting Currency
- USD
- Investor Line
- 425 279 8002
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 15.2
- Price/Book
- 4.0
Growth
- Revenue
- +115.1%
- EPS
- -151.5%
- Free Cash Flow
- -19.4%
Profitability
- Gross Margin
- 48.8%
- Operating Margin
- -171.5%
- Net Margin
- -173.0%
- ROE
- -68.8%
- ROIC
- -42.7%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 7.32
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.